Clinical Trials and Results

With every trial, we aim to solve challenges and unlock possibilities. Our trials adhere to the highest standards of safety and equity, and our commitment to advancing healthcare is reflected in our rigorous study protocols and the relentless pursuit of new, effective treatments.

Study ID	Study Description	Intervention	Study Phase/Type	Recruitment Status* / ClinicalTrials.gov Identifier (if applicable)
EN3835-309 PFI	A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of EN3835 vs Placebo in the Treatment of Plantar Fibromatosis (PFI)	Collagenase clostridium histolyticum EN3835	Phase 3/ Interventional	Recruiting NCT06151197
MNK19013059	A Multicenter, Randomized, Placebo Controlled, Double-Blind Trial to Assess the Safety and Efficacy of Terlipressin in Japanese Participants with Hepatorenal Syndrome (HRS)	Terlipressin	Phase 3 / Interventional	Recruiting

In the last five years, we’ve completed the following company-sponsored trials:

Study ID	Study Description	Study Treatment	Clinical Study Results
EN3225-001	Open-Label Pilot Study Assessing the Efficacy and Safety of New Formulations of Percocet® in the Treatment of Low Back Pain	PERCOCET® (oxycodone hydrochloride and acetaminophen USP) Tablets	PDF
EN3225-002	A Single-center, Randomized, Double-blind, Placebo-controlled, Single-dose Study of the Safety and Efficacy of Low-dose Percocet® Compared to OxyContin® in Patients With Acute Pain Following Third Molar Extraction	PERCOCET® (oxycodone hydrochloride and acetaminophen USP) Tablets	PDF
EN3225-003	A Single-Center, Randomized, Double-Blind, Placebo-Controlled, Single-Dose Study of the Safety and Efficacy of Low-Dose Percocet® in Patients With Acute Pain Following Third Molar Extraction	PERCOCET® (oxycodone hydrochloride and acetaminophen USP) Tablets	PDF
EN3835-210	A Phase 2, Double-blind, Randomized, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of EN3835 vs Placebo in the Treatment of Plantar Fibromatosis	Collagenase clostridium histolyticum EN3835	Completed NCT04496167
EN3835-222	A Phase 2, Double-blind, Randomized, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of EN3835 vs Placebo in the Treatment of Plantar Fibromatosis	Collagenase clostridium histolyticum EN3835	Completed NCT05152173
EN3835-223	An Observational, Double-blind (Sponsor Open), Long-term Study to Evaluate the Safety and Durability (Efficacy) of Response to EN3835 compared to Placebo in the Treatment of Adhesive Capsulitis of the Shoulder (Frozen Shoulder)	No treatment to be administered	Completed NCT04680156
EN3835-306	A Multi-Center, Open-Label, Extension Study to Evaluate the Long-Term Safety, Efficacy, and Durability of EN3835 in the Treatment and Retreatment of Plantar Fibromatosis.	Collagenase clostridium histolyticum EN3835	Completed NCT05254457
EN3000-101	An Open-Label, Randomized, Parallel-Group, Three Treatment Arm, Multicenter Study on Hypogonadal Males to Evaluate the Effect on 24-Hour Ambulatory Blood Pressure After 16-Week Continuous Treatment with Marketed Testosterone Products	AVEED® TESTIM® FORTESTA®	Completed NCT04456296
EN3835-227 PFA	A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging Study to Assess The Efficacy, Safety, and Tolerability of EN3835 vs Placebo in the Treatment of Plantar Fasciitis (PFA)	Collagenase clostridium histolyticum EN3835	Completed NCT06169319
MNK14084113	Impact of Acthar on Everyday Life of Participants with Severe Keratitis	Acthar® Gel (repository corticotropin injection)	Completed NCT04169061
MNK14274069	Acthar Gel for Multiple Sclerosis That Keeps Getting Better and Worse (RRMS) (OPTIONS)	Acthar® Gel (repository corticotropin injection)	NCT04169060
MNK19013058	Study To Confirm Efficacy and Safety of Terlipressin in Hepatorenal Syndrome (HRS) Type 1	Terlipressin	Completed NCT02770716

Studies for Discontinued Opioid Products